23 Sep 2020 07:00
Notice of Full Year Results
Oxford, UK; 23 September 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the Clinical AI company, will announce its Full Year Results for the 12 months ended 30 April 2020 on Wednesday 30th September 2020.
Lord (Paul) Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will host a virtual briefing for analysts and investors at 14.00 BST on the day of the results.
Details of the webcast, and the presentation slides, will be available via the Company website. For more details please contact CSCSensynehealth@consilium-comms.com.
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson, Chief Executive Officer |
|
Michael Norris, Interim Chief Financial Officer |
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
Dr Christopher Golden |
|
James Steel |
|
Oliver Jackson |
|
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma |
|
Euan Brown |
|
Consilium Strategic Communications | +44 (0) 7780600290 |
Mary-Jane Elliott |
|
Sukaina Virji |
|
Melissa Gardiner |
|
CSCSensynehealth@consilium-comms.com |
|
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com